{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:49:31Z","timestamp":1791452971781,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03811-0","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:53:29Z","timestamp":1791449609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Characteristics, Treatment Patterns, and Clinical Outcomes of Patients Initiated on Macitentan\/Tadalafil Single-Tablet Combination Therapy in the United States"],"prefix":"10.1007","author":[{"given":"Mrinalini","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kolaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Sandros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita D.","family":"Adhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2310-3793","authenticated-orcid":false,"given":"David","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gearhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"3811_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-97","volume":"8","author":"D Montani","year":"2013","unstructured":"Montani D, G\u00fcnther S, Dorfm\u00fcller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013;8:97. https:\/\/doi.org\/10.1186\/1750-1172-8-97.","journal-title":"Orphanet J Rare Dis"},{"issue":"25","key":"3811_CR2","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385(25):2361\u201376. https:\/\/doi.org\/10.1056\/NEJMra2000348.","journal-title":"N Engl J Med"},{"issue":"2","key":"3811_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.898122.","journal-title":"Circulation"},{"key":"3811_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. https:\/\/doi.org\/10.1136\/bmj.j5492.","journal-title":"BMJ"},{"issue":"10","key":"3811_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","volume":"14","author":"EMT Lau","year":"2017","unstructured":"Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603\u201314. https:\/\/doi.org\/10.1038\/nrcardio.2017.84.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3811_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40256-024-00694-w","volume":"25","author":"J Villanueva","year":"2025","unstructured":"Villanueva J, Wade J, Torres A, Hale G, Pham H. Sotatercept: the first FDA-approved activin A receptor IIA inhibitor used in the management of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2025;25(1):17\u201324. https:\/\/doi.org\/10.1007\/s40256-024-00694-w.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"3811_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1413687.","journal-title":"N Engl J Med"},{"issue":"1","key":"3811_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02148-2018","volume":"53","author":"N Gali\u00e8","year":"2019","unstructured":"Gali\u00e8 N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1):1802148. https:\/\/doi.org\/10.1183\/13993003.02148-2018.","journal-title":"Eur Respir J"},{"issue":"4","key":"3811_CR9","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325. https:\/\/doi.org\/10.1183\/13993003.01325-2024.","journal-title":"Eur Respir J"},{"issue":"38","key":"3811_CR10","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"issue":"1","key":"3811_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-024-03026-1","volume":"42","author":"CD Vizza","year":"2025","unstructured":"Vizza CD, et al. Clinical characteristics and treatment of patients diagnosed with pulmonary arterial hypertension: a real-world study in the USA, Europe and Japan. Adv Ther. 2025;42(1):193\u2013215.","journal-title":"Adv Ther"},{"issue":"4","key":"3811_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1164\/rccm.202404-0816OC","volume":"211","author":"PJ Leary","year":"2025","unstructured":"Leary PJ, Le RJ, Panjabi S, et al. Location of care delivery for pulmonary arterial hypertension in the United States. Am J Respir Crit Care Med. 2025;211(4):619\u201327. https:\/\/doi.org\/10.1164\/rccm.202404-0816OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3811_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40256-022-00553-6","volume":"23","author":"S Qadus","year":"2023","unstructured":"Qadus S, Naser AY, Ofori-Asenso R, Ademi Z, Al Awawdeh S, Liew D. Adherence and discontinuation of disease-specific therapies for pulmonary arterial hypertension: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023;23(1):19\u201333. https:\/\/doi.org\/10.1007\/s40256-022-00553-6.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7 Suppl","key":"3811_CR14","first-page":"S119","volume":"25","author":"KB Highland","year":"2019","unstructured":"Highland KB, Dumitrescu D, Mancini D, et al. Ensuring appropriate access to pulmonary arterial hypertension therapy. Am J Manag Care. 2019;25(7 Suppl):S119\u201327.","journal-title":"Am J Manag Care"},{"issue":"4","key":"3811_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, Jansa P, Fan F, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83(4):473\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.045.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3811_CR16","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s12325-026-03525-3","volume":"43","author":"HJ Ford","year":"2026","unstructured":"Ford HJ, Chin KM, Fan F, et al. Long-term treatment with single-tablet combination of macitentan and tadalafil in pulmonary arterial hypertension: results from A\u00a0DUE and its open-label period. Adv Ther. 2026;43(5):2106\u201324. https:\/\/doi.org\/10.1007\/s12325-026-03525-3.","journal-title":"Adv Ther"},{"key":"3811_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03159-x","author":"F Fan","year":"2025","unstructured":"Fan F, Davis S, Burbridge C, et al. Single-tablet combination therapy of macitentan\/tadalafil for patients with pulmonary arterial hypertension: qualitative interview study of the A\u00a0DUE phase\u00a03 trial. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03159-x.","journal-title":"Adv Ther"},{"key":"3811_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1156081","volume":"14","author":"Q Wei","year":"2023","unstructured":"Wei Q, Zhou J, Li H, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis. Front Pharmacol. 2023;14:1156081. https:\/\/doi.org\/10.3389\/fphar.2023.1156081.","journal-title":"Front Pharmacol"},{"key":"3811_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.977110","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:977110. https:\/\/doi.org\/10.3389\/fcvm.2022.977110.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"3811_CR20","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.chest.2023.10.010","volume":"164","author":"JGE Zelt","year":"2023","unstructured":"Zelt JGE, Weatherald J, Mathai SC. Ambitions for pulmonary arterial hypertension composite end points: a chain is only as strong as its weakest link. Chest. 2023;164(6):1350\u20133.","journal-title":"Chest"},{"issue":"1","key":"3811_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.36469\/jheor.2025.138006","volume":"12","author":"C Paoli","year":"2025","unstructured":"Paoli C, et al. Assessing upfront treatment patterns for newly initiated patients with pulmonary arterial hypertension in the United States. J Health Econ Outcomes Res. 2025;12(1):213.","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03811-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:53:30Z","timestamp":1791449610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03811-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":21,"alternative-id":["3811"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03811-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mrinalini Krishnan serves as a consultant for Johnson & Johnson, Liquidia, and United Therapeutics and is on the speakers bureau for Liquidia. Nicholas A Kolaitis declares no conflicts of interest. Marinella Sandros is an employee of Johnson & Johnson. Ankita D. Adhia is an employee of Johnson & Johnson. David Lopez is an employee of Johnson & Johnson. Natalie Gearhart is an employee of Johnson & Johnson. Alexander K Salomon is an employee of Putnam Associates, a consultancy that received funding from Johnson & Johnson in connection with this research. John J. Ryan serves as a consultant for Merck, Johnson & Johnson, United Therapeutics, and Kiniksa.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified, retrospective real-world data and did not involve interventional procedures with human participants. The study protocol was reviewed and approved by North Star Review Board, USA which granted the study a Not Human Subject Research determination. The analysis complied with the Health Insurance Portability and Accountability Act of 1996 and applicable data protection and privacy regulations. No patient-identifiable information was collected, and informed consent was not required. No proprietary risk calculator, scale, or index was reproduced in the manuscript. Risk categories were abstracted from chart documentation as recorded by participating HCPs and not independently adjudicated, which may introduce classification variability.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}